<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">ol{margin:0;padding:0}table td,table th{padding:0}.c28{border-right-style:solid;padding:3pt 6pt 3pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:top;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#ffffff;border-left-style:solid;border-bottom-width:1pt;width:252pt;border-top-color:#cccccc;border-bottom-style:solid}.c37{border-right-style:solid;padding:5pt 7pt 5pt 7pt;border-bottom-color:#2e5090;border-top-width:1pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;background-color:#e8edf5;border-left-style:solid;border-bottom-width:1pt;width:504pt;border-top-color:#2e5090;border-bottom-style:solid}.c42{border-right-style:solid;padding:7pt 10pt 7pt 10pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;background-color:#e8edf5;border-left-style:solid;border-bottom-width:0pt;width:504pt;border-top-color:#000000;border-bottom-style:solid}.c25{border-right-style:solid;padding:0pt 5.8pt 0pt 5.8pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#6bac3a;vertical-align:top;border-right-color:#000000;border-left-width:2.2pt;border-top-style:solid;background-color:#eff6e8;border-left-style:solid;border-bottom-width:0pt;width:6pt;border-top-color:#000000;border-bottom-style:solid}.c39{border-right-style:solid;padding:4pt 6pt 4pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:middle;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#2e5090;border-left-style:solid;border-bottom-width:1pt;width:252pt;border-top-color:#cccccc;border-bottom-style:solid}.c30{border-right-style:solid;padding:3pt 6pt 3pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:top;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#f2f2f2;border-left-style:solid;border-bottom-width:1pt;width:168pt;border-top-color:#cccccc;border-bottom-style:solid}.c33{border-right-style:solid;padding:3pt 6pt 3pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:top;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#f2f2f2;border-left-style:solid;border-bottom-width:1pt;width:252pt;border-top-color:#cccccc;border-bottom-style:solid}.c26{border-right-style:solid;padding:3pt 6pt 3pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:top;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#ffffff;border-left-style:solid;border-bottom-width:1pt;width:168pt;border-top-color:#cccccc;border-bottom-style:solid}.c20{border-right-style:solid;padding:4pt 6pt 4pt 6pt;border-bottom-color:#cccccc;border-top-width:1pt;border-right-width:1pt;border-left-color:#cccccc;vertical-align:middle;border-right-color:#cccccc;border-left-width:1pt;border-top-style:solid;background-color:#2e5090;border-left-style:solid;border-bottom-width:1pt;width:168pt;border-top-color:#cccccc;border-bottom-style:solid}.c14{border-right-style:solid;padding:5pt 7pt 5pt 7pt;border-bottom-color:#000000;border-top-width:0pt;border-right-width:0pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:0pt;border-top-style:solid;background-color:#eff6e8;border-left-style:solid;border-bottom-width:0pt;width:498pt;border-top-color:#000000;border-bottom-style:solid}.c47{padding-top:8pt;border-bottom-color:#6bac3a;border-bottom-width:1pt;padding-bottom:0pt;line-height:1.0;border-bottom-style:solid;orphans:2;widows:2;text-align:center}.c11{padding-top:3pt;border-bottom-color:#2e5090;border-bottom-width:0.5pt;padding-bottom:0pt;line-height:1.0;border-bottom-style:solid;orphans:2;widows:2;text-align:left}.c10{padding-top:2pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left;height:10.5pt}.c4{padding-top:1pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left;height:10.5pt}.c12{margin-left:18pt;padding-top:5pt;padding-bottom:2pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c0{color:#333333;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:10.5pt;font-family:"Arial";font-style:normal}.c3{margin-left:36pt;padding-top:1.5pt;padding-bottom:1.5pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c35{padding-top:6pt;padding-bottom:3pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c7{padding-top:0pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c2{padding-top:0pt;padding-bottom:2pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c52{padding-top:0pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:right}.c24{padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c41{padding-top:4pt;padding-bottom:2pt;line-height:1.0;orphans:2;widows:2;text-align:center}.c38{padding-top:0pt;padding-bottom:4pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c32{padding-top:2pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c43{padding-top:10pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c45{padding-top:30pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c44{padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:center}.c15{padding-top:20pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c29{padding-top:0pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:center}.c17{font-size:8pt;font-family:"Arial";font-style:italic;color:#6bac3a;font-weight:700}.c34{font-size:8pt;font-family:"Arial";font-style:italic;color:#666666;font-weight:400}.c22{font-size:9pt;font-family:"Arial";font-style:italic;color:#6bac3a;font-weight:400}.c49{font-size:8pt;font-family:"Arial";color:#666666;font-weight:400}.c18{font-size:14pt;font-family:"Arial";color:#2e5090;font-weight:700}.c16{font-size:9.5pt;font-family:"Arial";color:#333333;font-weight:400}.c27{border-spacing:0;border-collapse:collapse;margin-right:auto}.c6{font-size:10.5pt;font-family:"Arial";color:#333333;font-weight:400}.c46{font-size:11pt;font-family:"Arial";color:#2e5090;font-weight:700}.c50{font-size:13pt;font-family:"Arial";color:#666666;font-weight:400}.c40{font-size:9pt;font-family:"Arial";color:#2e5090;font-weight:700}.c23{font-size:10.5pt;font-family:"Arial";color:#2e5090;font-weight:700}.c1{font-size:10pt;font-family:"Arial";color:#333333;font-weight:400}.c21{font-size:9pt;font-family:"Arial";color:#6bac3a;font-weight:700}.c51{font-size:9.5pt;font-family:"Arial";color:#666666;font-weight:400}.c48{font-size:24pt;font-family:"Arial";color:#2e5090;font-weight:700}.c53{font-size:7pt;font-family:"Arial";color:#666666;font-weight:400}.c13{font-size:10pt;font-family:"Arial";color:#ffffff;font-weight:700}.c31{font-size:10pt;font-family:"Arial";color:#6bac3a;font-weight:700}.c8{font-size:10pt;font-family:"Arial";color:#333333;font-weight:700}.c5{font-size:10pt;font-family:"Arial";color:#6bac3a;font-weight:400}.c36{background-color:#ffffff;max-width:504pt;padding:54pt 54pt 54pt 54pt}.c9{height:0pt}.c19{height:10.5pt}.title{padding-top:0pt;color:#333333;font-size:28pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}.subtitle{padding-top:18pt;color:#666666;font-size:24pt;padding-bottom:4pt;font-family:"Georgia";line-height:1.0;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:left}li{color:#333333;font-size:10.5pt;font-family:"Arial"}p{margin:0;color:#333333;font-size:10.5pt;font-family:"Arial"}h1{padding-top:0pt;color:#2e74b5;font-size:16pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}h2{padding-top:0pt;color:#2e74b5;font-size:13pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}h3{padding-top:0pt;color:#1f4d78;font-size:12pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}h4{padding-top:0pt;color:#2e74b5;font-size:10.5pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;font-style:italic;orphans:2;widows:2;text-align:left}h5{padding-top:0pt;color:#2e74b5;font-size:10.5pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}h6{padding-top:0pt;color:#1f4d78;font-size:10.5pt;padding-bottom:0pt;font-family:"Arial";line-height:1.0;orphans:2;widows:2;text-align:left}</style></head><body class="c36 doc-content"><div><p class="c52"><span class="c34">QMSR Compliance FAQ &nbsp;| &nbsp;DP Distribution &amp; Consulting</span></p></div><p class="c19 c45"><span class="c0"></span></p><p class="c29"><span class="c48">QMSR COMPLIANCE FAQ</span></p><p class="c41"><span class="c50">For ISO 13485 Certified Medical Device Manufacturers</span></p><p class="c19 c47"><span class="c0"></span></p><p class="c43 c19"><span class="c0"></span></p><p class="c29"><span class="c46">Effective Date: February 2, 2026</span></p><p class="c44"><span class="c51">Reference: 21 CFR Part 820 (QMSR) | ISO 13485:2016 | CP 7382.850</span></p><p class="c19 c43"><span class="c0"></span></p><p class="c44"><span class="c22">Updated February 2026 to incorporate FDA Compliance Program CP 7382.850</span></p><p class="c43 c19"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c42" colspan="1" rowspan="1"><p class="c38"><span class="c46">ABOUT THIS DOCUMENT</span></p><p class="c2"><span class="c8">Audience: </span><span class="c1">Quality professionals at ISO 13485:2016 certified medical device manufacturers</span></p><p class="c2"><span class="c8">Purpose: </span><span class="c1">Clarify what QMSR changes, what stays the same, and practical implications for compliance</span></p><p class="c2"><span class="c8">Sources: </span><span class="c1">QMSR Final Rule (89 FR 7496, Feb 2, 2024), ISO 13485:2016, ISO 9000:2015, CP 7382.850 (Jan 30, 2026)</span></p><p class="c7"><span class="c8">Note: </span><span class="c1">All citations reference specific Preamble comment numbers, regulatory sections, and CP 7382.850 page references. Where FDA has deferred guidance, that uncertainty is stated plainly.</span></p></td></tr></table><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 1</span></p><p class="c11"><span class="c18">What does QMSR actually change versus what stays the same?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">The requirements are substantially similar. The real shift is not in what you must do, but in how compliance is evaluated, what records are now accessible to FDA, and the enforcement framework &mdash; which moved from QSIT&rsquo;s checklist-based subsystem model to a risk-based inspection process organized around six QMS Areas and four OAFRs under CP 7382.850.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">FDA&rsquo;s own characterization: &ldquo;substantially similar&rdquo; requirements</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA states this rulemaking &ldquo;does not fundamentally alter the requirements for a QS that exist in either the former QS regulation or the new QMSR&rdquo; (Comments 17&ndash;18, pages 7504&ndash;7505)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The concepts and requirements of the old QS Regulation, &ldquo;when viewed holistically, are contained in ISO 13485&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This is not a massive overhaul of what you must do &mdash; it is a restructuring of how compliance is framed and enforced</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What specifically IS new or changed:</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Record-keeping: </span><span class="c1">Enhanced record-keeping requirements in &sect; 820.35 (complaint handling records) and &sect; 820.45 (device labeling and packaging controls)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Inspection access: </span><span class="c1">The &sect; 820.180(c) exemption that protected internal audit records, management review records, and supplier audit records from routine FDA inspection has been removed (Comment 55, pages 7513&ndash;7515)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Terminology: </span><span class="c1">QMSR adopts ISO 9000:2015 Clause 3 vocabulary by reference &mdash; terms like &ldquo;customer,&rdquo; &ldquo;nonconformity,&rdquo; and &ldquo;verification&rdquo; now use ISO definitions unless FDA has explicitly redefined them in &sect; 820.3 (Comment 26)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Risk-based approach: </span><span class="c1">ISO 13485 more explicitly integrates risk-based thinking across Clauses 4.1, 7.1, 7.3, 7.4, 7.5, 7.6, and 8.2 (Comment 19, pages 7504&ndash;7505)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Inspection framework: </span><span class="c1">FDA has retired QSIT and published CP 7382.850 (January 30, 2026), replacing the four-subsystem checklist approach with a risk-based inspection process organized around six QMS Areas and four OAFRs (CP 7382.850, Part III, page 20)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What stays the same:</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Scope: applies to finished device manufacturers, not component makers or third-party servicers</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA&rsquo;s legal inspection authority under Section 704 of the FD&amp;C Act</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Core QMS expectations: design controls, production controls, CAPA, complaint handling, document control</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">How combination product CGMP requirements work under 21 CFR Part 4</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">ISO 13485 certificates do not replace FDA inspections; FDA inspections do not issue ISO certificates</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">For ISO-certified companies, the gap is not primarily in new requirements &mdash; it is in new enforcement exposure. What was previously shielded from FDA view is now visible, the inspection framework has shifted from checklists to risk-based process tracing, and the enforcement lens has moved from &ldquo;did you document it&rdquo; to &ldquo;can you prove people actually do it.&rdquo;</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comments 17&ndash;18 (pp. 7504&ndash;7505); Comment 19 (pp. 7504&ndash;7505); Comment 26 (p. 7506); Comment 55 (pp. 7513&ndash;7515); CP 7382.850 Part III (p. 20); FD&amp;C Act &sect; 704</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 2</span></p><p class="c11"><span class="c18">What do I specifically need to do to be QMSR compliant if I am already ISO 13485 certified?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">Your ISO 13485 certification covers the vast majority of QMSR requirements. Your gap analysis should focus on FDA-specific additions, terminology alignment, new record accessibility, and preparing for the risk-based inspection process defined in CP 7382.850 &mdash; not just the ISO standard.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c23">Step 1: </span><span class="c6">Start with a targeted gap analysis, not a full rebuild</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">QMSR incorporates ISO 13485:2016 by reference &mdash; your existing certified system is the foundation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Focus your analysis on the specific areas where FDA adds to, amends, or supplements ISO 13485</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Review your QMS documentation to ensure it references the correct regulatory framework (21 CFR Part 820 as amended, not just ISO 13485)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c23">Step 2: </span><span class="c6">Check for FDA-specific additions on top of ISO 13485</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Complaint handling: </span><span class="c1">&sect; 820.35 &mdash; complaint handling records with specific investigation, documentation, and UDI requirements</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Labeling/Packaging: </span><span class="c1">&sect; 820.45 &mdash; specific U.S. requirements for device labeling and packaging controls</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">UDI requirements: </span><span class="c1">Part 830 &mdash; UDI documentation requirements that go beyond ISO 13485 scope</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Definitions: </span><span class="c1">QMSR adds definitions in &sect; 820.3 that differ from or supplement ISO 9000/ISO 13485 definitions where U.S. law requires it</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c23">Step 3: </span><span class="c6">Align vocabulary with ISO 9000:2015 Clause 3</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">QMSR incorporates ISO 9000:2015 vocabulary by reference (Comment 26)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Terms like &ldquo;customer,&rdquo; &ldquo;supplier,&rdquo; &ldquo;nonconformity,&rdquo; and &ldquo;verification&rdquo; must be understood as defined in ISO 9000 unless QMSR &sect; 820.3 provides a different definition</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Note: this is ISO 9000 (vocabulary), not ISO 9001 (requirements) &mdash; only the definitions section applies</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c23">Step 4: </span><span class="c6">Prepare for the new enforcement exposure</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Review internal audit records, management review minutes, and supplier audit reports for investigation-readiness</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Ensure these records demonstrate substantive engagement, not just checkbox compliance</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">ISO certification alone will not satisfy FDA (Comment 80: &ldquo;FDA disagrees with the comments that recommend the Agency accept certification to ISO 13485 in place of FDA inspections&rdquo;)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c23">Step 5: </span><span class="c6">Prepare for the new inspection structure</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Study CP 7382.850&rsquo;s six QMS Areas and four OAFRs &mdash; this is how investigators will walk through your system (CP 7382.850, Attachment A, pages 70&ndash;78)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Verify your QMS covers all applicable requirements, including those outside ISO 13485 (Parts 803 MDR, 806 corrections/removals, 821 tracking, 830 UDI)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Ensure your system can be navigated by ISO 13485 clause references, not just legacy QS Regulation paragraph numbers</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Your ISO certification is a strong starting point, not a finish line. The practical work is in reviewing FDA-specific supplements, preparing internal records for potential inspection, and ensuring your system can be demonstrated through the lens of CP 7382.850&rsquo;s risk-based inspection framework.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 26 (p. 7506); Comment 80 (pp. 7517&ndash;7518); &sect; 820.3; &sect; 820.35; &sect; 820.45; 21 CFR Parts 803, 806, 821, 830; CP 7382.850 Attachment A (pp. 70&ndash;78)</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 3</span></p><p class="c11"><span class="c18">How will FDA inspections and investigations be different under QMSR?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">FDA published CP 7382.850 on January 30, 2026 &mdash; a 78-page Compliance Program Manual that replaces QSIT and fundamentally restructures how inspections are planned, scoped, executed, and escalated. The framework shifts from QSIT&rsquo;s four subsystems to six QMS Areas and four OAFRs, driven by product risk to patients and users. Internal audit, management review, and supplier audit records are now fully accessible.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">The new inspection framework: CP 7382.850</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Published January 30, 2026, effective February 2, 2026 (CP 7382.850, Cover Page)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Supersedes CP 7382.845 and CP 7383.001 (PMA pre/postmarket inspections) &mdash; consolidating everything into a single compliance program</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">78-page operating manual that tells investigators exactly how to plan, scope, execute, and escalate inspections under QMSR</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">From QSIT subsystems to QMS Areas and OAFRs (CP 7382.850, Part III, pages 20&ndash;24)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 1: </span><span class="c1">Management Oversight &mdash; QMS planning, risk-based approach, management commitment, management review, human resources, planning of product realization</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 2: </span><span class="c1">Design and Development &mdash; full design lifecycle from customer processes through design files</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 3: </span><span class="c1">Production and Service Provision &mdash; infrastructure, work environment, process validation, identification and traceability</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 4: </span><span class="c1">Outsourcing and Purchasing &mdash; supplier controls, purchasing processes, purchased product verification</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 5: </span><span class="c1">Change Control &mdash; QMS changes, software changes, product and process changes, purchasing changes</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">QMS Area 6: </span><span class="c1">Measurement, Analysis, and Improvement &mdash; feedback, complaint handling, internal audits, CAPA, nonconforming product, data analysis</span></p><p class="c4"><span class="c0"></span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">OAFR 1: </span><span class="c1">Medical Device Reporting (21 CFR 803)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">OAFR 2: </span><span class="c1">Reports of Corrections and Removals (21 CFR 806)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">OAFR 3: </span><span class="c1">Medical Device Tracking Requirements (21 CFR 821)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">OAFR 4: </span><span class="c1">Unique Device Identification (21 CFR 830)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Two inspection models (CP 7382.850, Figures 1&ndash;3, pages 23&ndash;25)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Model 1 (risk-selected): </span><span class="c1">For non-baseline surveillance, compliance follow-up, for-cause, SPRA, and PMA postmarket inspections. Investigators select at least one element from each of the six QMS Areas and evaluate each of the four OAFRs. Selection is driven by identified product risks.</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Model 2 (prescriptive): </span><span class="c1">For baseline surveillance (no prior FDA inspection or MDSAP audit history) and PMA preapproval inspections. Specifies particular elements within each QMS Area that must be evaluated &mdash; minimum 22 elements for non-sterile devices, 23 for sterile. More prescriptive and comprehensive.</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The critical record access change (Comment 55 + CP 7382.850)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under the old QS Regulation, &sect; 820.180(c) exempted management review, internal audit, and supplier audit records from routine FDA inspection</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under QMSR, this exemption is explicitly removed &mdash; &ldquo;FDA disagrees that it should maintain the exceptions set forth at &sect; 820.180(c)&rdquo; (Comment 55)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 operationalizes this: Management Review is an element within the Management Oversight QMS Area; Internal Audits are an element within Measurement, Analysis, and Improvement (Attachment A, pages 73, 75)</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c39" colspan="1" rowspan="1"><p class="c29"><span class="c13">Under QSIT (Old)</span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c29"><span class="c13">Under CP 7382.850 (New)</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Four subsystems: CAPA, Production &amp; Process Controls, Design Controls, Management Controls</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Six QMS Areas + four OAFRs, organized around product risk to patients/users</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Checklist-oriented, structured sequence</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Risk-based, flexible &mdash; QMS Areas not required to be evaluated in a specific order</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">&sect; 820.180(c) protected internal audit and management review records</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Protection removed &mdash; investigators can request and review these records</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">CAPA reviewed in both Level 1 and Level 2 inspections</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">CAPA is one element in MA&amp;I &mdash; required under Model 2 but not mandatory in Model 1</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Sampling tables guided how many records to review</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">No sampling tables &mdash; investigators select records based on risk and professional judgment</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">QSIT guide directed investigators</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">CP 7382.850 is the single operating manual for all device inspection types</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">Key operational changes</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Risk management documentation is the inspection roadmap &mdash; investigators review it throughout the inspection to decide which areas to prioritize and which records to sample (CP 7382.850, Part III.1.B, page 21)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators expand scope if objectionable conditions are found or if evaluating one requirement necessitates evaluating requirements in other areas &mdash; creating a direct feedback loop (page 21)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under FDARA, delaying, denying, limiting, or refusing an inspection &mdash; including refusing to provide requested documentation &mdash; can cause a device to be deemed adulterated (CP 7382.850, Part I.1, page 7)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">MDSAP considerations</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">MDSAP-participating firms remain exempt from routine surveillance inspections (CP 7382.850, pages 26&ndash;28)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">However, they remain subject to for-cause, compliance follow-up, SPRA, and PMA-related inspections</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA continues to review and classify MDSAP audit reports; concerns raised by that review can trigger an FDA inspection</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">CP 7382.850 is the most transparent look FDA has ever given industry at how it plans to inspect. Read it. The framework is risk-driven, record-access barriers are gone, and investigators will follow risk signals through your quality system rather than checking boxes in a fixed sequence.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">CP 7382.850 (Jan 30, 2026): Cover Page, Part I.1 (p. 7), Part III.1 (pp. 20&ndash;24), Figures 1&ndash;3 (pp. 23&ndash;25), Attachment A (pp. 70&ndash;78); Comment 55 (pp. 7513&ndash;7515); FDARA &sect; 301(k); FD&amp;C Act &sect;&sect; 510(h), 704</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 4</span></p><p class="c11"><span class="c18">What process will the FDA inspectors follow under QMSR?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">FDA published the answer: CP 7382.850 details a risk-based inspection process where investigators use your risk management documentation as the roadmap, select elements within six QMS Areas based on product risk to patients, and can move flexibly across areas as findings dictate. There are no fixed sampling tables &mdash; record selection is driven by risk and investigator judgment.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">The inspection process step by step (CP 7382.850, Part III.1.B, pages 20&ndash;22)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 1 &mdash; Preparation: </span><span class="c1">Investigators become familiar with the manufacturer&rsquo;s roles, products, and processes to understand what requirements are applicable</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 2 &mdash; Risk identification: </span><span class="c1">Investigators identify product risks that could adversely impact patients and/or users, reviewing registration and listing, marketing authorizations, previous 483 observations, recalls, MDR data, and the inspection assignment</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 3 &mdash; Risk documentation review: </span><span class="c1">Investigators review the manufacturer&rsquo;s risk management documentation throughout the inspection to understand product risks and associated risk controls</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 4 &mdash; Element selection: </span><span class="c1">Based on identified risks, the investigator selects elements within QMS Areas and OAFRs to evaluate. QMS Areas are not required to be evaluated in any specific order.</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 5 &mdash; Requirement evaluation: </span><span class="c1">The investigator evaluates related requirements within selected elements, reviewing multiple records to provide assurance</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Step 6 &mdash; Scope expansion: </span><span class="c1">If objectionable conditions are found, or if evaluating one requirement necessitates evaluating others, investigators expand scope into additional elements and areas</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Inspection types and which model applies (CP 7382.850, Figure 3, page 25)</span></p><table class="c27"><tr class="c9"><td class="c20" colspan="1" rowspan="1"><p class="c29"><span class="c13">Inspection Type</span></p></td><td class="c20" colspan="1" rowspan="1"><p class="c29"><span class="c13">Model</span></p></td><td class="c20" colspan="1" rowspan="1"><p class="c29"><span class="c13">Trigger</span></p></td></tr><tr class="c9"><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Non-baseline surveillance</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">1</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Previous inspection/MDSAP with NAI or VAI classification</span></p></td></tr><tr class="c9"><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">Baseline surveillance</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">2</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">No prior FDA inspection or MDSAP audit history</span></p></td></tr><tr class="c9"><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Compliance follow-up</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">1</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Previous regulatory action; verify corrective actions</span></p></td></tr><tr class="c9"><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">For-cause</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">1</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">Signal, complaint, MDR increase, recall, fraud suspicion</span></p></td></tr><tr class="c9"><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Specific Product Risk (SPRA)</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">1</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">CDRH-initiated; specific product risk identified</span></p></td></tr><tr class="c9"><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">PMA preapproval</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">2</span></p></td><td class="c30" colspan="1" rowspan="1"><p class="c7"><span class="c16">PMA application; focused on subject device</span></p></td></tr><tr class="c9"><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">PMA postmarket</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">1</span></p></td><td class="c26" colspan="1" rowspan="1"><p class="c7"><span class="c16">Post PMA approval monitoring</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">No sampling tables &mdash; a significant change from QSIT</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 contains no sampling tables and does not direct investigators on how many records to review</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators select records based on identified product risks and professional judgment</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">&ldquo;Multiple records should be reviewed to provide assurance&rdquo; &mdash; but specifics are left to the investigator</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This is more flexible for FDA and less predictable for manufacturers</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Risk management failures as OAI triggers (CP 7382.850, Part V.1.A, pages 50&ndash;51)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Situation 1 examples: </span><span class="c1">Failure to establish, implement, or maintain one or more processes for risk management in product realization</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to use feedback or postmarket surveillance as inputs into risk management</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to control design and development, including not adequately evaluating changes for risk and impact on products</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to adequately analyze data or utilize current risk information, resulting in decisions not to proceed with investigations or corrective actions, leading to unmitigated adverse health consequences</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">These findings can result from underestimated risk, outdated risk information, or inadequate risk management used to make decisions</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What your team must be ready for</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators who move across QMS Areas following risk threads, not a fixed checklist sequence</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Requests for risk management documentation early in the inspection &mdash; this is their roadmap</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Questions about how risk-based decisions were made, with documented rationale, not just outcomes</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Potential requests for internal audit reports, management review records, and supplier audit documentation &mdash; refusal can trigger adulteration under FDARA</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Scope expansion if early findings reveal problems &mdash; a weak area triggers broader coverage</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">The inspection framework is no longer a mystery. CP 7382.850 is publicly available and tells you exactly how investigators will approach your facility. Organizations that study it, prepare their risk management documentation as the inspection entry point, and can demonstrate compliance across the six QMS Areas will be best positioned.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">CP 7382.850: Part III.1.B (pp. 20&ndash;22), Figures 1&ndash;3 (pp. 23&ndash;25), Part V.1.A Situation 1 (pp. 50&ndash;51); FDARA &sect; 301(k); FD&amp;C Act &sect; 510(h)</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 5</span></p><p class="c11"><span class="c18">Will the FDA evaluate &ldquo;culture of quality&rdquo; differently now that the ISO 13485 standard is legally required?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">Yes. FDA defined &ldquo;culture of quality&rdquo; in the QMSR Preamble as meeting regulatory requirements through &ldquo;behaviors, attitudes, activities, and processes.&rdquo; CP 7382.850 carries this language directly into the inspection framework, citing it in a footnote on page 20 and making Management Oversight a full QMS Area with elements that evaluate whether leadership is actually driving quality.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">FDA&rsquo;s definition &mdash; now embedded in the inspection framework</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Comment 27 (pages 7506&ndash;7507): &ldquo;FDA expects medical device manufacturers, led by individuals with executive responsibilities, to embrace a culture of quality as a key component in ensuring the manufacture of safe and effective medical devices.&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">&ldquo;A culture of quality meets regulatory requirements through a set of behaviors, attitudes, activities, and processes.&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 quotes this language directly in footnote 10 (page 20): &ldquo;FDA expects top management to ensure applicable regulatory requirements are met through integrating QMS processes and embracing a culture of quality.&rdquo;</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Management Oversight as a full QMS Area (CP 7382.850, Attachment A, page 73)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Management Oversight is one of the six QMS Areas &mdash; not a background check but a core inspection area</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Elements include: Management Commitment (Clause 5.1), Quality Policy and Objectives (Clauses 5.3, 5.4), Management Review (Clauses 5.6.1&ndash;5.6.3), Human Resources (Clause 6.2), and Risk-based Approach (Clause 4.1.2)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under both inspection models, investigators must evaluate at least one element from Management Oversight &mdash; and under Model 2, Management Review is a required element</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Why this matters more under QMSR than under QSR</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under QSR: management review and internal audit records were protected from FDA inspection via &sect; 820.180(c)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under QMSR + CP 7382.850: these records are now accessible, meaning FDA can see whether leadership engagement is substantive or performative</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 explicitly instructs investigators to evaluate whether management reviews consist of boilerplate vs. active decision-making &mdash; disconnects between review records and actual complaint/CAPA trends will be visible</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What FDA investigators will look for in management review records</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Evidence of: </span><span class="c1">Clear inputs: quality data, CAPA/complaint signals, supplier performance, audit results</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Decision-making: </span><span class="c1">Explicit priorities, resource assignments, and risk trade-offs with documented rationale</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Follow-through: </span><span class="c1">Assigned owners, due dates, and evidence of completion and effectiveness</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Compliance factor: </span><span class="c1">CP 7382.850 Part V.1.B (page 53) lists &ldquo;Manufacturer&rsquo;s Commitments&rdquo; as a compliance factor: evidence of &ldquo;commitment from top management&rdquo; and &ldquo;allocation of adequate resources&rdquo;</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Culture of quality is no longer aspirational &mdash; it has regulatory teeth. FDA defined it in the Preamble, embedded it in the inspection framework via CP 7382.850, and made the records that demonstrate (or fail to demonstrate) leadership engagement accessible to investigators.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 27 (pp. 7506&ndash;7507); CP 7382.850 Part III.1.A footnote 10 (p. 20), Attachment A Management Oversight (p. 73), Part V.1.B (p. 53); ISO 13485 Clauses 5.1, 5.6</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 6</span></p><p class="c11"><span class="c18">Does this mean that the FDA inspectors are doing the same thing as my ISO 13485 auditors?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">No. ISO 13485 auditors verify conformity to a voluntary international standard. FDA investigators verify compliance with U.S. law. CP 7382.850 makes the structural differences even more explicit: FDA inspections evaluate six QMS Areas plus four OAFRs (MDR, corrections/removals, tracking, UDI) that extend well beyond ISO 13485&rsquo;s scope.</span></p></td></tr></table><p class="c19 c24"><span class="c0"></span></p><p class="c12"><span class="c6">The core distinction</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">ISO 13485 auditors assess your QMS against the standard&rsquo;s requirements</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA investigators verify compliance with the FD&amp;C Act and all implementing regulations &mdash; including not only QMSR but also Parts 803 (MDR), 806 (corrections/removals), 821 (tracking), and 830 (UDI)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 formalizes this by requiring investigators to evaluate four OAFRs in addition to the six QMS Areas &mdash; these OAFRs have no equivalent in ISO 13485 audits (Attachment A, page 77)</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c39" colspan="1" rowspan="1"><p class="c29"><span class="c13">ISO 13485 Audit</span></p></td><td class="c39" colspan="1" rowspan="1"><p class="c29"><span class="c13">FDA Inspection (CP 7382.850)</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Verifies conformity to the standard</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Verifies compliance with U.S. federal law</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Conducted by third-party auditing organizations</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Conducted by FDA investigators under Section 704 of FD&amp;C Act</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Results in a certificate of conformance</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Results in EIR; may produce Form 483 or Warning Letter</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Scope: QMS requirements per ISO 13485</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Scope: 6 QMS Areas + 4 OAFRs (MDR, corrections/removals, tracking, UDI)</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Follows clause-by-clause assessment</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Risk-based process tracing; QMS Areas evaluated in any order based on risk</span></p></td></tr><tr class="c9"><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Findings: nonconformities, observations</span></p></td><td class="c33" colspan="1" rowspan="1"><p class="c7"><span class="c16">Findings: inspectional observations; Situation 1 can trigger OAI and enforcement</span></p></td></tr><tr class="c9"><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Scheduled audit cycle</span></p></td><td class="c28" colspan="1" rowspan="1"><p class="c7"><span class="c16">Scheduled, for-cause, compliance follow-up, or SPRA &mdash; can be unannounced</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">FDA&rsquo;s explicit position (Comments 79&ndash;80, pages 7517&ndash;7518)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">&ldquo;FDA does not intend to require medical device manufacturers to obtain ISO 13485 certification&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">&ldquo;An ISO 13485 certificate will not be considered or accepted as a substitute for any oversight processes, including the performance of an inspection under section 704 of the FD&amp;C Act&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">&ldquo;FDA inspections will not result in the issuance of a certificate of conformity to ISO 13485&rdquo;</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Your ISO auditor and your FDA investigator are looking at overlapping but fundamentally different things, through different legal lenses, with different consequences. CP 7382.850&rsquo;s OAFRs make this especially clear: MDR compliance, UDI, corrections and removals, and tracking have no ISO 13485 equivalent.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comments 79&ndash;80 (pp. 7517&ndash;7518); CP 7382.850 Attachment A OAFRs (p. 77); FD&amp;C Act &sect; 704; 21 CFR Parts 803, 806, 821, 830</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 7</span></p><p class="c11"><span class="c18">What happens if the FDA finds discrepancies between my stated ISO 13485 policies and procedures, and actual practices?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">The &ldquo;say-do gap&rdquo; has always been an inspection risk. Under QMSR + CP 7382.850, the risk compounds: FDA can now see your internal audit records documenting the very gaps they discover on the floor, investigators are instructed to expand scope when findings reveal objectionable conditions, and repeat violations trigger a specific &ldquo;recidivist policy&rdquo; with escalating enforcement.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">The compounding exposure under QMSR</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">An FDA investigator finds that your SOP says one thing and your production floor does another</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Previously, your internal audit records &mdash; which may have documented this same gap &mdash; were shielded under &sect; 820.180(c)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under QMSR, the investigator can now request those internal audit records</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">If your own records show you knew about the discrepancy, you move from &ldquo;unaware noncompliance&rdquo; to &ldquo;documented awareness without adequate corrective action&rdquo;</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">CP 7382.850&rsquo;s scope expansion mechanism (Part III.1.B, page 21)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators &ldquo;should consider evaluating additional requirements, as applicable, if an inspection reveals objectionable conditions or if evaluation of one requirement necessitates the evaluation of requirements in other areas&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This creates a direct feedback loop: one weak area triggers broader inspection coverage across additional QMS Areas</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">A say-do gap found in production can lead the investigator into management review, CAPA, internal audit, and training records</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The enforcement continuum (CP 7382.850, Part V, pages 50&ndash;54)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">OAI triggers: </span><span class="c1">Situation 1 &mdash; Serious, systemic, and/or repeat deviations with evidence of adverse impact or significant risk to patients/users &rarr; OAI classification and potential regulatory action</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">VAI findings: </span><span class="c1">Situation 2 &mdash; Less significant deviations with minimal or no public health impact &rarr; VAI classification; Form 483 informs the establishment</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Key factor: </span><span class="c1">At each level, evidence that you were already aware of the issue (via your own audit records) strengthens FDA&rsquo;s position</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The recidivist policy (CP 7382.850, Part V.3.D, page 59)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA has a specific enforcement strategy for manufacturers with repeated violative inspections</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Recidivist Warning Letters require the manufacturer to submit annual certifications by an outside expert consultant confirming a complete QMS audit</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The CEO must personally certify receipt, review, and completion of all corrections and corrective actions</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDA notes this pattern &ldquo;is often due to the failure of the organization to effectively implement and maintain a quality management system&rdquo;</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The corrective action dimension</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">If your CAPA records show the gap was identified, a root cause was determined, and corrective actions were implemented and verified for effectiveness &mdash; this is a positive signal</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">If your audit records show the gap was identified but corrective actions were not completed, not effective, or not documented &mdash; this is a Situation 1 finding: &ldquo;Failure to adequately correct the same or similar significant deficiencies from previous inspections&rdquo; (Part V.1.A.(1)(f), page 51)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Even documented struggles represent positive evidence if they demonstrate systematic identification and response</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Under QMSR + CP 7382.850, the say-do gap is no longer just an inspection risk &mdash; it is an evidence chain that FDA can trace through your own records. The best protection is not hiding problems but demonstrating systematic identification, response, and resolution. Repeat failures trigger a specific escalation pathway.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 55 (pp. 7513&ndash;7515); CP 7382.850: Part III.1.B (p. 21), Part V.1.A Situation 1 (pp. 50&ndash;51), Part V.3.D Recidivist Policy (p. 59); ISO 13485 Clauses 8.2.4, 8.5.2, 8.5.3</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 8</span></p><p class="c11"><span class="c18">What are these 83 industry &ldquo;comments&rdquo; I keep hearing about?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">The 83 comments are FDA&rsquo;s organized responses to public input on the proposed QMSR rule, published in the Preamble of the Final Rule. They are the closest thing to FDA &ldquo;showing their work.&rdquo; CP 7382.850 frequently cites these comments, making them the interpretive foundation for the new inspection framework.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">What the Preamble is</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The QMSR Final Rule was published in the Federal Register on February 2, 2024 (Vol. 89, No. 23, pages 7496&ndash;7530)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Before the rule was finalized, FDA published a proposed rule and invited public comments from manufacturers, trade associations, auditing organizations, and other stakeholders</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The Preamble to the Final Rule contains FDA&rsquo;s organized responses to these comments, numbered Comment 1 through Comment 83</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">How they are organized</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section A: </span><span class="c1">General Comments on Proposed Rule (Comments 1&ndash;16)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section B: </span><span class="c1">Scope (Comments 2&ndash;7)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section C: </span><span class="c1">Incorporation by Reference (Comments 8&ndash;15)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section D: </span><span class="c1">Definitions (Comments 16&ndash;32)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section E: </span><span class="c1">Requirements for a QMS, Clarification of Concepts, and Supplementary Provisions (Comments 33&ndash;77)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Section F: </span><span class="c1">Implementation Strategy &mdash; inspections, MDSAP, certification (Comments 78&ndash;83)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The connection to CP 7382.850</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 directly cites the Preamble comments as interpretive authority &mdash; for example, footnote 10 (page 20) quotes Comment 27 on culture of quality</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The compliance program references FDA&rsquo;s response to Comment 19 on risk management as the basis for its risk-based inspection approach (footnote 5, page 8)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Read them together: the Preamble explains what FDA intends; CP 7382.850 operationalizes how investigators will evaluate it</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The most consequential comments</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Comment 19: </span><span class="c1">Risk management &mdash; FDA&rsquo;s expectations for risk-based thinking throughout the full product lifecycle, now operationalized as OAI triggers in CP 7382.850</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Comment 27: </span><span class="c1">Culture of quality &mdash; FDA&rsquo;s definition as &ldquo;behaviors, attitudes, activities, and processes,&rdquo; now quoted in the inspection framework</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Comment 55: </span><span class="c1">Removal of &sect; 820.180(c) exemptions &mdash; internal audit, management review, and supplier audit records now accessible to FDA, operationalized through Management Oversight and MA&amp;I QMS Areas</span></p><p class="c3"><span class="c5">&bull; </span><span class="c8">Comments 78&ndash;81: </span><span class="c1">Inspection approach, MDSAP alignment, and FDA&rsquo;s position on ISO certification &mdash; now concretely answered by CP 7382.850</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Read the Preamble and CP 7382.850 as companion documents. The Preamble explains what FDA intends and why. CP 7382.850 tells investigators how to evaluate it. Together, they form the most complete picture available of what QMSR compliance looks like in practice.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Federal Register Vol. 89, No. 23 (Feb 2, 2024), pp. 7496&ndash;7530; CP 7382.850 footnotes 5 (p. 8), 10 (p. 20); Comments 1&ndash;83 organized by topic</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 9</span></p><p class="c11"><span class="c18">What internal audit documents, previously confidential under ISO 13485, are now fair game for QMSR inspections?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">Important nuance: these records were never &ldquo;confidential under ISO 13485.&rdquo; The protection came from the old QS Regulation at &sect; 820.180(c) and the QSIT guide. Under QMSR, that protection is explicitly removed. CP 7382.850 operationalizes this by placing Internal Audits and Management Review as inspectable elements. And under FDARA, refusing to provide requested documentation can cause a device to be deemed adulterated.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">Clarifying the source of the old protection</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The old QS Regulation &sect; 820.180(c) specifically exempted management review records, internal audit reports, and supplier audit reports from routine FDA inspection</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The QSIT inspection guide reinforced this by directing investigators not to routinely request these records</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">ISO 13485 itself never contained such an exemption &mdash; other regulators worldwide have always had access to these records</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Where these records now sit in the inspection framework (CP 7382.850, Attachment A)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Internal Audits &mdash; an element within the Measurement, Analysis, and Improvement QMS Area (page 75), referencing ISO 13485 Clause 8.2.4</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Management Review &mdash; an element within the Management Oversight QMS Area (page 73), referencing Clauses 5.6.1, 5.6.2, 5.6.3</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Outsourcing (which includes supplier audits) &mdash; an element within the Outsourcing and Purchasing QMS Area (page 76), referencing Clause 4.1.5</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under Model 2 (baseline/PMA preapproval), Internal Audits and Management Review are required elements that must be evaluated (Figure 2, page 24)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Specific record categories now accessible to FDA</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Internal audit plans, schedules, scope, and criteria</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Internal audit findings, conclusions, and corrective actions</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Management review inputs (quality data, CAPA, complaints, audit results, supplier performance)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Management review outputs (decisions, action items, resource allocation, improvement plans)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Supplier audit reports and supplier qualification records</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Gap assessments and improvement plans</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The FDARA dimension &mdash; refusing documentation carries consequences (CP 7382.850, Part I.1, page 7)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">FDARA amended the FD&amp;C Act so that a device is &ldquo;deemed to be adulterated&rdquo; if the establishment &ldquo;delays, denies, or limits an FDA inspection or refuses to permit entry or inspection&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This includes refusing to provide requested documentation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">An inadvertent refusal based on outdated assumptions about what FDA can and cannot see could create a serious compliance problem</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Every person who may interact with an FDA investigator needs to understand that the &sect; 820.180(c) protection no longer exists</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">How to write internal records in this new environment</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Write internal audit findings as though they will be read by an FDA investigator &mdash; because they now can be</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Document findings factually and objectively, with clear corrective action plans and timelines</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Ensure management review records demonstrate active leadership engagement, not just meeting attendance</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">A finding with documented corrective action is evidence of a healthy system; a finding without follow-through is evidence of a broken one</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">The protection is gone, and refusing to produce these records carries legal consequences under FDARA. These are no longer internal-only documents &mdash; they are potential investigation evidence. Write them with the same care and precision you would apply to any externally-facing compliance documentation.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 55 (pp. 7513&ndash;7515); CP 7382.850: Part I.1 FDARA (p. 7), Attachment A &mdash; MA&amp;I (p. 75), Management Oversight (p. 73), Outsourcing and Purchasing (p. 76), Figure 2 (p. 24); FDARA &sect; 301(k)</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 10</span></p><p class="c11"><span class="c18">How does QMSR treat risk management differently than the old QS Regulation?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">Risk management under QMSR is not a standalone activity &mdash; it is the operating logic of the entire QMS. CP 7382.850 makes this concrete: risk management is one of the two stated goals of every FDA inspection, investigators use your risk management documentation as the roadmap throughout, and risk management failures are explicitly listed as Situation 1 OAI triggers.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">From design-phase requirement to system-wide expectation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under the old QS Regulation, risk management was most explicitly referenced in Design Controls (&sect; 820.30)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under QMSR, ISO 13485 embeds risk-based thinking across the entire standard &mdash; Clauses 4.1, 7.1, 7.3, 7.4, 7.5, 7.6, and 8.2 all contain risk-related requirements</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Comment 19 (pages 7504&ndash;7505): FDA expects manufacturers to consider risk throughout the total product lifecycle, using risk management as an input to product realization, supplier management, production, and postmarket activities</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Risk management in the inspection framework (CP 7382.850)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">The stated goal of FDA inspections includes evaluating whether &ldquo;risk management and risk-based decision making are effectively used in the QMS&rdquo; (Part II.1, page 15)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Diagram 1 (page 20) places patients and users at the center of inspections, surrounded by a ring representing risk management &mdash; this is the new operating philosophy</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators &ldquo;review the manufacturer&rsquo;s risk management documentation throughout the inspection to assist with understanding product risks and associated risk controls&rdquo; (Part III.1.B, page 21)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Risk-based Approach is a standalone element within the Management Oversight QMS Area, mapping to Clause 4.1.2(b) (Attachment A, page 73)</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Risk management failures as explicit OAI triggers (Part V.1.A, pages 50&ndash;51)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to establish, implement, or maintain one or more processes for risk management in product realization</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to use feedback or postmarket surveillance as inputs into risk management for monitoring and maintaining product realization or improvement processes</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to control design and development, including not adequately evaluating changes for risk and impact on products prior to implementation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to ensure processes, including changes, are adequately monitored, controlled, or evaluated for risk and impact on products prior to implementation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Failure to adequately analyze data or utilize current risk information, resulting in decisions not to proceed with investigations or corrective actions, leading to unmitigated adverse health consequences &mdash; including from underestimated risk, outdated risk information, or inadequate risk management</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Practical implications for ISO-certified companies</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Your ISO 14971 risk management file is no longer just a design-phase deliverable &mdash; it is the investigator&rsquo;s primary navigation tool</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Risk-based decisions must be traceable: documented rationale for what was prioritized, what was accepted, and what was escalated</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Postmarket data (complaints, MDRs, CAPA trends) must feed back into risk management files &mdash; the compliance program explicitly flags failure to do so as an OAI trigger</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Risk management documentation must be current, not a static artifact from product launch</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Risk management is no longer an ancillary expectation under QMSR &mdash; it is one of the two stated goals of every FDA device inspection, and deficiencies in risk management can directly drive enforcement action. If your risk management documentation is outdated, incomplete, or disconnected from postmarket reality, CP 7382.850 treats that as a serious finding.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 19 (pp. 7504&ndash;7505); CP 7382.850: Part II.1 (p. 15), Diagram 1 (p. 20), Part III.1.B (p. 21), Part V.1.A Situation 1 (pp. 50&ndash;51), Attachment A Management Oversight (p. 73); ISO 13485 Clauses 4.1, 7.1; ISO 14971</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 11</span></p><p class="c11"><span class="c18">What role do on-the-job activity systems play in QMSR compliance?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">ISO 13485 Clause 6.2 requires not just training, but evaluation of the effectiveness of actions taken to ensure competence. CP 7382.850 places Human Resources as an element within the Management Oversight QMS Area, meaning investigators will evaluate whether your workforce can actually demonstrate competence &mdash; not just whether they completed a training course.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">The regulatory foundation: ISO 13485 Clause 6.2</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Clause 6.2(b): &ldquo;Determine the necessary competence for personnel performing work affecting product quality&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Clause 6.2(d): &ldquo;Ensure that its personnel are aware of the relevance and importance of their activities and how they contribute to the achievement of the quality objectives&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Clause 6.2(f): &ldquo;Evaluate the effectiveness of the actions taken&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This is not a training completion requirement &mdash; it is a competence verification and effectiveness evaluation requirement</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">Where this sits in the inspection framework (CP 7382.850)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Human Resources is an element within the Management Oversight QMS Area, mapping to Clause 6.2 (Attachment A, page 73)</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under Model 2 (baseline/PMA preapproval), Management Oversight elements are specifically evaluated</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Under both models, investigators evaluating any QMS Area may follow the thread into Human Resources if competence appears to be a factor in a finding</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850&rsquo;s scope expansion mechanism means a competence gap found in one area can trigger evaluation of training and effectiveness records across the QMS</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The gap between training records and demonstrated competence</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Traditional training systems produce completion records: employee X completed course Y on date Z</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Clause 6.2 requires more than this &mdash; it requires evidence that the training was effective: that the employee can actually perform the work competently</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This is the &ldquo;knowing-doing gap&rdquo; &mdash; the difference between passing a quiz and consistently applying requirements in daily work</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">On-the-job activity systems bridge this gap by documenting real workplace behaviors that demonstrate competence</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What this means for compliance documentation</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Activity-based evidence &mdash; documented demonstrations of correct behavior in actual work scenarios &mdash; is more robust than training certificates alone</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">When an investigator asks &ldquo;how do you verify that your operators are competent to perform this process?&rdquo; &mdash; a training record shows awareness; an activity record shows capability</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This applies across all roles: production operators, QA personnel, design engineers, supervisors, and management</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Clause 6.2 does not say &ldquo;train people.&rdquo; It says &ldquo;ensure competence&rdquo; and &ldquo;evaluate effectiveness.&rdquo; CP 7382.850 places this requirement within the Management Oversight QMS Area, linking workforce competence directly to leadership accountability. On-the-job activity systems provide the evidence that bridges the gap between training completion and demonstrated competence.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">ISO 13485 Clause 6.2; CP 7382.850 Attachment A Management Oversight (p. 73), Part III.1.B scope expansion (p. 21); Comment 27 (pp. 7506&ndash;7507)</span></p><hr style="page-break-before:always;display:none;"><p class="c7 c19"><span class="c0"></span></p><p class="c15"><span class="c31">FAQ 12</span></p><p class="c11"><span class="c18">How can activity-based systems help strengthen organizational quality culture?</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c25" colspan="1" rowspan="1"><p class="c7 c19"><span class="c0"></span></p></td><td class="c14" colspan="1" rowspan="1"><p class="c2"><span class="c21">KEY TAKEAWAY</span></p><p class="c32"><span class="c1">FDA&rsquo;s definition of quality culture &mdash; &ldquo;behaviors, attitudes, activities, and processes&rdquo; &mdash; maps directly to activity-based compliance systems. CP 7382.850 carries this language into the inspection framework and makes Management Oversight a core evaluation area. Activity-based systems produce the contemporaneous behavioral evidence that demonstrates culture in action, not just culture on paper.</span></p></td></tr></table><p class="c24 c19"><span class="c0"></span></p><p class="c12"><span class="c6">The regulatory alignment</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Comment 27 defines culture of quality through four elements: behaviors, attitudes, activities, and processes</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 footnote 10 (page 20) embeds this definition directly in the inspection framework: &ldquo;FDA expects top management to ensure applicable regulatory requirements are met through integrating QMS processes and embracing a culture of quality&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Activity-based systems address two of the four elements directly (activities and behaviors) and influence the other two (attitudes and processes) through practice and feedback</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">What activity-based compliance evidence looks like</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Documented workplace activities that demonstrate correct application of regulatory requirements in real scenarios</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Push-Do-Reflect cycles: employee receives a task tied to a specific regulatory requirement, performs it in their actual work environment, and reflects on the experience</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Supervisory verification that activities were completed correctly &mdash; not just that training was attended</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Records organized by role and regulatory requirement, creating traceable evidence of competence across the workforce</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">How this aligns with CP 7382.850&rsquo;s inspection logic</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators evaluating Management Oversight will look at Human Resources (Clause 6.2) for competence verification evidence</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Investigators evaluating any QMS Area will look for evidence that the people performing the work understand and can demonstrate the applicable requirements</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Activity records provide contemporaneous evidence &mdash; generated at the time of the work &mdash; rather than retroactive documentation created in preparation for an inspection</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">This aligns with the CP&rsquo;s emphasis on evaluating whether a QMS &ldquo;actually functions as an integrated, risk-driven whole&rdquo; rather than whether it merely exists on paper</span></p><p class="c10"><span class="c0"></span></p><p class="c12"><span class="c6">The investigation-readiness dimension</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">CP 7382.850 Part V.1.B (page 53) evaluates the &ldquo;Manufacturer&rsquo;s Commitments&rdquo; including &ldquo;commitment from top management&rdquo; and &ldquo;allocation of adequate resources to ensure the firm&rsquo;s quality management system is operating in a state of control&rdquo;</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Activity-based records demonstrate this commitment concretely: leadership invested in ongoing competence development, not just one-time training</span></p><p class="c3"><span class="c5">&bull; </span><span class="c1">Even findings of competence gaps, when documented with corrective actions, demonstrate that the system is identifying and responding to issues &mdash; which is exactly what FDA wants to see</span></p><p class="c10"><span class="c0"></span></p><table class="c27"><tr class="c9"><td class="c37" colspan="1" rowspan="1"><p class="c2"><span class="c40">BOTTOM LINE</span></p><p class="c32"><span class="c1">Activity-based compliance systems are not a replacement for traditional training. They are the verification of effectiveness that Clause 6.2 requires and that CP 7382.850 will evaluate. They produce the behavioral evidence that gives substance to FDA&rsquo;s definition of quality culture &mdash; turning &ldquo;behaviors, attitudes, activities, and processes&rdquo; from aspirational language into documented reality.</span></p></td></tr></table><p class="c4"><span class="c0"></span></p><p class="c35"><span class="c17">Key Citations: </span><span class="c34">Comment 27 (pp. 7506&ndash;7507); CP 7382.850: footnote 10 (p. 20), Attachment A Management Oversight/Human Resources (p. 73), Part V.1.B (p. 53); ISO 13485 Clause 6.2</span></p><div><p class="c29"><span class="c49">Page </span><span class="c53">&nbsp; | &nbsp;21 CFR Part 820 (QMSR) | ISO 13485:2016 | CP 7382.850</span></p></div></body></html>